<DOC>
	<DOCNO>NCT01489878</DOCNO>
	<brief_summary>In prospective , observational , multicentric open study , investigator compare acquisition rate methicillin-resistant staphylococci ( coagulase-negative staphylococci Staphylococcus aureus ) nasal carriage community patient receive ambulatory antibiotic treatment either β-lactam ( amoxicillin-clavulanate penicillin M ) , macrolide , synergistin fluoroquinolone .</brief_summary>
	<brief_title>Antibiotics Use Carriage Methicillin-resistant Staphylococci Community Patients</brief_title>
	<detailed_description>Rationale : Recent spread community-acquired , methicillin-resistant Staphylococcus aureus ( CA-MRSA ) represent major Public Health concern . MR coagulase-negative staphylococci ( MR-CoNS ) likely reservoir MR determinant Staphylococcal Cassette Chromosome mec ( SCCmec ) S. aureus ( SA ) . Amoxicillin-clavulanic acid , penicillins M , macrolides synergistin prescribed antistaphylococcal antibiotic French community , respective impact nasal colonization MR-CoNS SA investigate population . Primary objective : To compare acquisition rate MR-CoNS nasal carriage community patient treat β-lactams ( amoxicillin-clavulanate penicillin M ) , macrolides , synergistin fluoroquinolones end antibiotherapy . Secondary objective : ( ) To compare acquisition rate MR-CoNS nasal carriage community patient treat β-lactams ( amoxicillin-clavulanate penicillin M ) , macrolides , synergistin fluoroquinolones 23 45 day end antibiotherapy ; ( ii ) To describe frequency co-colonization SA MR-CoNS antibiotic use ; ( iii ) To compare selection pressure 4 class antibiotic term antibiotic resistance associate MR carriage strain staphylococci ( iv ) To assess biodiversity SCCmec community-acquired MR-CoNS . Sudy design method : investigator propose perform prospective , multicentric study MR staphylococci carriage community patient receive antibiotic prescribe general practitioner ( GP ) . Patients old 18 , treat β-lactams ( amoxicillin-clavulanate penicillin M ) , macrolides , synergistin fluoroquinolones minimal expect duration 5 day ( whatever indication ) consent study protocol eligible inclusion . Hospitalization within previous 6 month , antibiotherapy within previous 2 month , second line antibiotherapy inclusion constitute exclusion criterion . Demographic medical data collect inclusion . Three sample nasal flora obtain included patient : ( ) first one antibiotic exposure ( inclusion , patient 's GP ) ( ii ) second third one GP 's office end 23 45 day termination antibiotherapy , respectively . Enrolled patient participate study 5 7 week , depend duration antibiotherapy . Samples transfer Bacteriology unit BICHAT-Claude Bernard hospital MR-CoNS S. aureus carriage screen , antibiotic susceptibility test SCCmec characterization multiplex PCR . Number patient ( duration study ) , statistical analysis : Carriage rate MR-CoNS community 10 % -20 % . Expected acquisition rate 20 % patient treat penicillin M amoxicilline-clavulanic acid , le 5 % patient treat synergistin . Acquisition rate predictable macrolides group . To demonstrate significant difference acquisition rate ( power = 90 % , α risk = 5 % ) , 578 patient definitively include ( 141 group , include anticipated 25 % -rate patient lose follow-up ) , total study duration 22 month . Number participate GP : 48 GP Paris suburb , affiliate Department General Medicine BICHAT medical school-Paris 7 University .</detailed_description>
	<mesh_term>Staphylococcal Infections</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Methicillin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Antibiotics , Antitubercular</mesh_term>
	<criteria>INCLUSION CRITERIA : Age old 18 Prescription General Practitioner ( investigator ) βlactam ( amoxicillinclavulanate penicillin M ) , macrolide , synergistin fluoroquinolone minimal expect duration 5 day ( whatever indication ) Informed consent study protocol NONINCLUSION CRITERIA : Hospitalization within previous 6 month Antibiotherapy within previous 2 month Combination antibiotherapy EXCLUSION CRITERIA : Prescription secondline antibiotherapy inclusion Withdrawal inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Coagulase-negative staphylococci</keyword>
	<keyword>Staphylococcus epidermidis</keyword>
	<keyword>Staphylococcus aureus</keyword>
	<keyword>Anti-bacterial agent</keyword>
	<keyword>Drug resistance , Microbial</keyword>
	<keyword>Methicillin resistance</keyword>
	<keyword>Β-lactams</keyword>
	<keyword>Fluoroquinolones</keyword>
	<keyword>Macrolides</keyword>
	<keyword>Synergistin</keyword>
	<keyword>General practitioner</keyword>
	<keyword>Antibiotic selection pressure</keyword>
	<keyword>Ambulatory antibiotherapy</keyword>
	<keyword>Community patient</keyword>
</DOC>